ArticleJournal of clinical practice and research2025
Sirtuin 1 and Sirtuin 2 Gene Expressions in Colorectal Cancers.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the immunoreactivity of sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) in colorectal cancer tissues using immunohistochemistry and to investigate their potential roles in the diagnosis and prognosis of colorectal cancer. Materials and Methods: Colon specimens from 104 patients diagnosed with colorectal adenocarcinoma at SBÜ Kartal Dr. Lütfi Kırdar City Hospital between 2016 and 2021 were analyzed. Immunohistochemical staining was performed to assess the immunoreactivity of SIRT1 and SIRT2. Associations between the clinicopathological parameters of colorectal cancer patients and the expression levels of SIRT1 and SIRT2 (categorized as low or high) were examined. Results: SIRT1 expression was significantly associated with K-RAS mutations (p=0.021) but showed no significant association with N-RAS (p=0.114) or B-RAF (p=0.624) mutations. SIRT2 expression levels were significantly associated with TNM stage (p=0.043), presence of metastasis (p=0.004), K-RAS mutations (p=0.047), and N-RAS mutations (p=0.020). Co-expression of SIRT1 and SIRT2 was significantly correlated with TNM stage (p=0.041), presence of metastasis (p=0.012), and mutations in K-RAS (p=0.028) and N-RAS (p=0.022). Conclusion: SIRT2 expression levels were significantly correlated with TNM classification, as well as the presence of metastasis. In contrast, SIRT1 expression was not significantly associated with these parameters. Both SIRT1 and SIRT2 showed a statistically significant relationship with K-RAS mutations, highlighting their potential roles in the molecular pathology of colorectal cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.